No Data
China Resources Double-Crane Pharmaceutical (600062.SH): Subsidiary passed GMP compliance inspection.
On January 3, Gelonghui reported that China Resources Double-Crane Pharmaceutical (600062.SH) announced that its wholly-owned subsidiary, Henan Double-Crane Huali Pharmaceutical Co., Ltd. (referred to as "Double-Crane Huali"), received the "Pharmaceutical GMP Compliance Inspection Notification" issued by the Henan Provincial Drug Administration. The company has passed the pharmaceutical GMP compliance inspection, indicating that the company's product production quality management meets GMP requirements. This will benefit the company in maintaining stable product quality and a consistent production capacity to meet the market demand for related pharmaceuticals. The results of this pharmaceutical GMP compliance inspection will not have a significant impact on the company's performance.
A Piece Of The Puzzle Missing From China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Share Price
China Resources Double-Crane Pharmaceutical Passes Generic Drug Evaluation for Pentazocine Injection
China Resources Double-Crane Pharmaceutical (600062.SH): The injection of Pethidine hydrochloride has passed the consistency evaluation of generics in terms of quality and efficacy.
On December 30, Gelonghui reported that China Resources Double-Crane Pharmaceutical (600062.SH) announced that the company received the "Notification of Approval for Supplementary Application of Pharmaceutical" (Notification No.: 2024B06197) issued by the National Medical Products Administration for the injectable pethidine solution (referred to as "the Pharmaceutical"). The injectable pethidine solution is suitable for various kinds of chronic major pain, such as cancer pain, traumatic pain, and postoperative pain, and can also be used for preoperative or pre-anesthesia administration as an auxiliary medication for surgical anesthesia.
China Resources Double-Crane Pharmaceutical Plans Up to 500-Million-Yuan Investment in Financial Products
China Resources Double-Crane Pharmaceutical (600062.SH): DC10190 capsule has received the drug clinical trial approval notice.
Gelonghui reported on December 26 that China Resources Double-Crane Pharmaceutical (600062.SH) announced that its wholly-owned subsidiary Peking Double-Crane Run Technology Co., Ltd. received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for the DC10190 capsules. The DC10190 capsules are intended for the treatment of patients with advanced or metastatic solid tumors and are a type 1 new drug that has not yet been marketed domestically or internationally.
Earnings Update: Here's Why Analysts Just Lifted Their China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Price Target To CN¥24.91
No Data
